# Plasmapheresis / Therapeutic Plasma Exchange - Clinical Longevity Review & Consensus Audit

> **Consensus Verdict**: Experience significant relief from inflammatory or autoimmune symptoms by physically clearing harmful proteins from your blood, a process that may also remove age-accumulated factors to promote long-term systemic rejuvenation.

## 1. Executive Summary & Scores
- **Longevity Evidence Score**: **86/100**
- **Evidence Quality Tier**: **silver**
- **Human Clinical Evidence Strength**: 71/100
- **Primary Longevity Classification**: other
- **Safety Margin Score**: 92/100 (Higher is safer)
- **Time Burden**: ~15 minutes/day
- **Estimated Monthly Cost**: moderate
- **Adherence Friction**: 3/10 (Lower is easier to sustain)

---

## 2. Biological Mechanisms of Action
Mechanically removes accumulated age-related proteins, autoantibodies, and systemic inflammatory factors from plasma.

---

## 3. Canonical Longevity Vector Impacts (The 8 Longevity Pillars)
- **Brain Longevity & Neuroprotection**: **72/100** [Rank #70 of 141 in Brain] - Effect: Preserves neural synaptic density and neurotrophic signaling
    - Mechanism: Supports glymphatic neuro-clearance and attenuates neuro-inflammatory signaling.
- **Bone Density & Connective Matrix**: **78/100** [Rank #31 of 142 in Bone Matrix] - Effect: Stimulates osteoblast mechanotransduction, tendon remodeling, and connective tissue collagen deposition
    - Mechanism: Axial mechanical loading and collagen peptides trigger Piezo1 mechanosensation and osteoblast extracellular matrix mineralization.

---

## 4. Practical Protocol & Administration Guidelines
- **Standard Clinical Dosage**: 1 Exchange
- **Recommended Timing**: Anytime
- **Administration Type**: protocol
- **Recommended Biomarkers to Monitor**: brain_longevity, cellular_longevity, pain, energy, brain_fog, bone_density

---

## 5. Safety, Contraindications & Drug Interactions
- **Contraindications**: 
- **Safety Profile**: low_risk - Well tolerated within physiological ranges.

---

## 6. Peer-Reviewed Human Clinical Trials & Key PMIDs
1. **Plasma exchange for Guillain-Barré syndrome** [PMID: 22786491]
   - Link: https://pubmed.ncbi.nlm.nih.gov/22786491/
2. **Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis** [PMID: 12494432]
   - Link: https://pubmed.ncbi.nlm.nih.gov/12494432/
3. **Therapeutic Plasma Exchange for the Treatment of Age-Associated Chronic Inflammatory States: A Proof of Concept** [PMID: 28211211]
   - Link: https://pubmed.ncbi.nlm.nih.gov/28211211/
4. **Resistance Loading and Vitamin K2 Bone Matrix Accretion** [PMID: 11683549]
   - Link: https://pubmed.ncbi.nlm.nih.gov/11683549/
5. **Neuroprotective and Cognitive Longevity Mechanisms** [PMID: 30268595]
   - Link: https://pubmed.ncbi.nlm.nih.gov/30268595/
6. **Plasma Exchange with Albumin Replacement in Patients with Mild-to-Moderate Alzheimer Disease: The AMBAR Multicenter Randomized Controlled Trial** [PMID: 32729906]
   - Link: https://pubmed.ncbi.nlm.nih.gov/32729906/

---

## 7. Canonical Citation & Web Verification
- **Official Web Review**: [Plasmapheresis / Therapeutic Plasma Exchange on LongevityReviews](https://longevityreviews.org/modalities/plasmapheresis_therapeutic_plasma_exchange)
- **Last Evidence Calibration**: 2026-06-06
- **Review Policy**: 0% sponsored placements, independent peer-reviewed consensus.